168 related articles for article (PubMed ID: 3497179)
1. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
Schapira M; Ramus MA; Waeber B; Brunner HR; Jallat S; Carvallo D; Roitsch C; Courtney M
J Clin Invest; 1987 Aug; 80(2):582-5. PubMed ID: 3497179
[TBL] [Abstract][Full Text] [Related]
2. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
Patston PA; Roodi N; Schifferli JA; Bischoff R; Courtney M; Schapira M
J Biol Chem; 1990 Jun; 265(18):10786-91. PubMed ID: 2191958
[TBL] [Abstract][Full Text] [Related]
3. Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment.
Schapira M; Ramus MA; Jallat S; Carvallo D; Courtney M
J Clin Invest; 1986 Feb; 77(2):635-7. PubMed ID: 3484756
[TBL] [Abstract][Full Text] [Related]
4. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
5. Alpha 1-antitrypsin Pittsburgh (Met358-->Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation.
Wachtfogel YT; Bischoff R; Bauer R; Hack CE; Nuijens JH; Kucich U; Niewiarowski S; Edmunds LH; Colman RW
Thromb Haemost; 1994 Dec; 72(6):843-7. PubMed ID: 7740452
[TBL] [Abstract][Full Text] [Related]
6. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
7. Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.
Aulak KS; Davis AE; Donaldson VH; Harrison RA
Protein Sci; 1993 May; 2(5):727-32. PubMed ID: 8495195
[TBL] [Abstract][Full Text] [Related]
8. Major inhibitors of the contact phase coagulation factors.
Schapira M
Semin Thromb Hemost; 1987 Jan; 13(1):69-78. PubMed ID: 2436302
[No Abstract] [Full Text] [Related]
9. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock.
Aasen AO; Erichsen NS; Gallimore MJ; Amundsen E
Adv Shock Res; 1980; 4():1-10. PubMed ID: 6172027
[TBL] [Abstract][Full Text] [Related]
10. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
11. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma.
Gallimore MJ; Friberger P
Thromb Res; 1982 Feb; 25(3):293-8. PubMed ID: 6917564
[No Abstract] [Full Text] [Related]
12. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
Scott CF; Carrell RW; Glaser CB; Kueppers F; Lewis JH; Colman RW
J Clin Invest; 1986 Feb; 77(2):631-4. PubMed ID: 3484755
[TBL] [Abstract][Full Text] [Related]
13. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of plasma kallikrein-kinin system inhibitors from salivary glands of the blood-sucking insect Triatoma infestans.
Isawa H; Orito Y; Jingushi N; Iwanaga S; Morita A; Chinzei Y; Yuda M
FEBS J; 2007 Aug; 274(16):4271-86. PubMed ID: 17645545
[TBL] [Abstract][Full Text] [Related]
15. Cold promoted activation and factor XII, prekallikrein and C1-inhibitor.
Czendlik C; Lämmle B; Duckert F
Thromb Haemost; 1985 Apr; 53(2):242-4. PubMed ID: 2410997
[TBL] [Abstract][Full Text] [Related]
16. Alpha 1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
Scott CF; Carrell RW; Glaser CB; Lewis JH; Colman RW
Trans Assoc Am Physicians; 1985; 98():344-51. PubMed ID: 3879844
[TBL] [Abstract][Full Text] [Related]
17. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII.
Dors DM; Nuijens JH; Huijbregts CC; Hack CE
Thromb Haemost; 1992 Jun; 67(6):644-8. PubMed ID: 1509403
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel recombinant serpin with potential antithrombotic properties.
Hopkins PC; Crowther DC; Carrell RW; Stone SR
J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
[TBL] [Abstract][Full Text] [Related]
19. Prorenin-renin conversion by the contact activation system in human plasma: role of plasma protease inhibitors.
Derkx FH; Bouma BN; Schalekamp MA
J Lab Clin Med; 1984 Apr; 103(4):560-73. PubMed ID: 6366096
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor.
Esnouf MP; Burgess AI; Dodds AW; Sarphie AF; Miller GJ
Thromb Haemost; 2000 Jun; 83(6):874-81. PubMed ID: 10896241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
